| Cat.No. | Name | Information |
|---|---|---|
| M1973 | Ostarine | Ostarine (GTx-024 and MK-2866) is an investigational selective androgen receptor modulator (SARM) with Ki of 3.8 nM. |
| M6033 | Dihydrotestosterone | Dihydrotestosterone is an androgen (male hormone). Specifically it's the strongest of the androgens. It can be used to construct animal models of polycystic ovary syndrome (PCOS). |
| M5565 | Dexmedetomidine HCl | Dexmedetomidine Hydrochloride is an agonist of adrenergic alpha-2 receptor, which is used in veterinary medicine for its analgesic and sedative properties. |
| M5805 | Nandrolone | Nandrolone is a synthetic, anabolic steroid analog of testosterone. |
| M1839 | MDV3100 | MDV3100 is an orally bioavailable, organic, non-steroidal small molecule targeting the androgen receptor (AR) with potential antineoplastic activity. |
| M5764 | Medroxyprogesterone acetate | Medroxyprogesterone acetate (MPA) is a synthetic progestin and act as a potent progesterone receptor agonist, used to treat abnormal menstruation or irregular vaginal bleeding. |
| M2270 | Apalutamide (ARN-509) | Apalutamide (ARN-509) is a novel androgen receptor (AR) antagonist for the treatment of castration-resistant prostate cancer (CRPC). |
| M10306 | Bavdegalutamide (ARV-110) | Bavdegalutamide (ARV-110) is an oral, specific androgen receptor (AR) PROTAC degrader. |
| M29958 | AR antagonist 3 | AR antagonist 3 is a potent and selective androgen receptor (AR) antagonist with an IC50 of 0.47 µM. AR antagonist 3 exhibits a dose-dependent decrease of the FRET signal (IC50= 18.05 μM). AR antagonist 3 shows effective inhibition on tumor growth when administered intratumorally. |
| M29728 | Topilutamide | Topilutamide is a topical nonsteroidal antiandrogen (NSAA). |
| M29505 | ARD-69 | ARD-69 (compound 34) is a potent PROTAC androgen receptor degrader. ARD-69 induces degradation of androgen receptor (AR) protein in AR-positive prostate cancer cell lines. ARD-69 suppresses AR-regulated gene expression. |
| M29317 | UT-34 | UT-34 is a potent, selective and orally active second-generation pan-androgen receptor (AR) antagonist and degrader with IC50s of 211.7 nM, 262.4 nM and 215.7 nM for wild-type, F876L and W741L AR, respectively. UT-34 binds to ligand-binding domain (LBD) and function-1 (AF-1) domains and requires ubiquitin proteasome pathway to degrade the AR. UT-34 has anti-prostate cancer efficacy. |
| M29293 | EPI-7170 | EPI-7170, a ralaniten analogue, is a potent androgen receptor N-terminal structural domain antagonist that blocks the transcriptional activity of full-length AR (FL-AR) and AR splice variants (AR-Vs). EPI-7170 has antitumor effects against enzalutamide resistant castration-resistant prostate cancer (CRPC). |
| M29251 | JNJ-63576253 free base | JNJ-63576253 (TRC-253) free base is a potent and orally active full antagonist of androgen receptor (AR), with IC50s of 37 and 54 nM for F877L mutant AR and wild-type AR in LNCaP cells. JNJ-63576253 free base can be used for the research of castration-resistant prostate cancer (CRPC). |
| M29116 | (R)-UT-155 | (R)-UT-155 (compound 11) is a selective androgen receptor degrader (SARD) ligand. Less active than the S-isomer. |
| M28937 | Gumelutamide | Gumelutamide is a tetrahydropyridopyrimidine compound, acting as an antiandrogen, antineoplastic agent. Gumelutamide is an androgen antagonist. |
| M28761 | ODM-204 | ODM-204 is novel nonsteroidal dual inhibitor of both androgen receptor and CYP17A1 enzyme, with IC50s of 80 nM and 22 nM, respectively. |
| M28707 | VPC-14449 | VPC-14449 is a potent and selective inhibitor of the DNA-binding domain of the androgen receptor (AR-DBD), with IC50 of 0.34 μM for full-length human AR. VPC-14449 reduces the ability of full-length AR as well as AR variants to interact with chromatin. VPC-14449 can be used for the research of prostate cancer. |
| M28700 | Honokiol DCA | Honokiol DCA (Honokiol dichloroacetate) is a dichloroacetate analog of Honokiol. Honokiol DCA can inhibit the growth of human prostate cancer cells in vitro and suppress the androgen receptor (AR) protein level. |
| M28616 | Rezvilutamide | Rezvilutamide (SHR3680) is an androgen receptor antagonist. Rezvilutamide (SHR3680) is used for the study of prostate cancer. |
| M28268 | YK11 | YK11 is a partial agonist of androgen receptor, with osteogenic activity. |
| M28103 | Faznolutamide | Faznolutamide is an antiandrogen agent. |
| M20065 | WAY-298516 | WAY-298516 is a modulating rad51 |
| M14621 | S-23 | S-23 is an orally active selective androgen receptor modulator (SARM) with a Ki of 1.7 nM. |
| M10965 | ORM-15341 | ORM-15341 is a potent androgen receptor (AR) antagonist that acts on AR-HEK293 cells with an IC50 value of 38 nM. |
| M10959 | BMS-641988 | BMS-641988 is an androgen receptor (AR) inhibitor that may be used in studies related to prostate cancer. |
| M8699 | EPI-001 | EPI-001 is a specific inhibitor of the AR (androgen receptor) without inhibiting PR or GR transcriptional activities. EPI-001 can inhibit transactivation of the AR amino-terminal domain (NTD), with an IC50 of ~6 μM. EPI-001 is also a selective modulator of PPARγ. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.
